purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation exel earnings call period ending december image source motley fool exelixis exelq earnings callfeb pm etcontents prepared remark question answer call participant prepared remark operatorgood day lady gentleman welcome exelixis fourth quarter fiscal year financial result conference call name towanda operator today reminder call recorded replay purpose would like turn call host today m susan hubbard executive vice president public affair investor relation please proceedsusan hubbard executive vice president public affair investor relation thank towanda thank joining u exelixis fourth quarter fiscal year financial result conference call joining today call mike morrissey president ceo chris senner chief financial officer review progress fourth quarter full year ended december pj haley executive vice president commercial amy peterson chief medical officer dana aftab chief scientific officer also call today participate questionandanswer portion call call today refer financial measure calculated according generally accepted accounting principle please refer today press release posted website explanation reason using nongaap measure well table deriving measure gaap result course presentation making forwardlooking statement regarding future event future performance company includes statement possible development regarding discovery product development regulatory commercial financial strategic mattersshould invest exelixis right buy stock exelixis consider motley fool stock advisor analyst team identified believe best stock investor buy exelixis one stock made cut could produce monster return coming year stock advisor provides investor easytofollow blueprint success including guidance building portfolio regular update analyst two new stock pick month stock advisor service tripled return sp since see stock stock advisor return february actual event result could course differ materially refer document file time time sec heading risk factor identify important factor could cause actual result differ materially expressed company verbally writing today including without limitation risk uncertainty related product commercial success market competition regulatory review approval process conducting clinical trial compliance applicable regulatory requirement dependence collaboration partner level cost associated discovery product development business development commercialization activity turn call mike mike morrissey president chief executive officer right thank susan thanks everyone joining u call today exelixis strong year already sprinting busy january provided important update across literally component business pleased see continued growth cabozantinib franchise yous globally provides foundation effort advance drug discovery development priority outlined rd day december reviewed important news jumpstart corporate update january jpm healthcare conference reiterate everything today focus top highlight including first saw strong performance cabozantinib business fourth quarter full year continued growth demand revenue cabometyx maintained status leading tki rcc firstline io tki market secondline monotherapy segment fourth quarter cabo franchise net product revenue grew year year compared fourth quarter cabo franchise net product revenue grew full year compared full year highlighting role worldwide leading tki global cabozantinib franchise net product revenue generated exelixis partner approximately million billion fourth quarter full year respectively chris review financial guidance prepared remark second final reply brief submitted next week second msn trial took place october expect ruling first half obviously critical milestone company cabozantinib franchise speak specific today proud work team preparing presenting case exelixis continue vigorously protect intellectual property right respect cabo differentiated molecule pursue behalf patient cancer third made significant progress advancing pipeline highlighted rd day presentation december top priority advance potential new cabo indication net metastatic crpc recent contacto presentation asco gu generated lot buzz meeting amy sure address qa session shortly zanza development continues key priority u term existing new pivotal trial enrolling xb expansion cohort critical stage global network site contributing effort heard dana december ind pipeline full next year exciting new compound could address range solid tumor indication potentially differentiating profile based extensive preclinical testing please see press release issued hour ago fourth quarter full year financial result extensive list key corporate milestone achieved quarter turn call chrischris senner chief financial officer thanks mike fourth quarter company reported total revenue approximately million included cabozantinib franchise net product revenue approximately million cabometyx net product revenue million included approximately million clinical trial sale grosstonet cabozantinib franchise fourth quarter line expectation cabometyx trade inventory increased approximately unit compared third quarter approximately week hand increase inventory partially related timing holiday end beginning based see trade inventory utilized first week additionally estimating grosstonet full year approximately seen past grosstonet tends higher first quarter year primarily due higher medicare part copay assistance expense finally clinical trial sale historically choppy quarter expect continue future quarter total revenue also included approximately million collaboration revenue includes approximately million royalty earned partner ipsen takeda sale cabozantinib total operating expense fourth quarter approximately million compared million third quarter rd expense primary driver decline total operating expense primarily related lower licensing expense provision income tax fourth quarter approximately million compared provision income tax approximately million third quarter company reported gaap net income approximately million per share basic per share diluted fourth quarter company also reported nongaap net income approximately million per share basic per share diluted nongaap net income excludes impact approximately million stockbased compensation expense net related income tax effect cash investment year ended december approximately billion fourth quarter completed million share repurchase program announced march since commencement share repurchase program repurchased approximately million share average price level cash investment supported ongoing cash flow operation provides exelixis flexibility invest internal rd activity pursue external business development opportunity expand pipeline allows u return capital shareholder million share repurchase program announced january combining share repurchase program return billion shareholder end finally turning financial guidance full year announced financial guidance jpmorgan conference january detailed slide earnings presentation turn call back mikemike morrissey president chief executive officer right thanks chris wrap thanking entire exelixis team individual collective effort support range discovery development commercial activity great year shaping inflection point business science patient hope serve everexpanding basis want everyone know team highly motivated every single day excel mission help cancer patient recover stronger live longer look forward updating progress future thank continued support interest exelixis happy open call question question answer operatorthank operator instruction first question come line michael schmidt guggenheim line openmichael schmidt guggenheim partner analyst hey guy good afternoon thanks taking question pipeline question sort thinking potential opportunity zanzalitinib perhaps sort context recent cabo phase trial readout specifically question stellar study head neck cancer thought interesting recently initiated phase maybe remind u drive confidence zanzas clinical profile head neck think success probabilityamy peterson chief medical officer yeah thank mike amy thanks question getting stellar study design give u confidence think might referring recently reported failure pemlen setting actually believe stellar example smart risk phase design employed also given observed cabopem dovetailing earlier question leveraging cabo data exact example multicenter phase study recently published dr saba nature earlier year conducted patient operable recurrent metastatic head neck cancer study tavopembro demonstrated response rate month medianfree survival month median overall survival phase benchmark well monotherapy pembro keynote study orr study zanzapembro versus monotherapy pembro looking beating response rate around doublet zanzapembro also benchmark well phase lenpem study demonstrated orr medianfree progression sorry median progressionfree survival eight month know leap study negative obviously going review data carefully public ass modification need made think also observed combination pemlen difficulty physician regard maintaining dose density len lot toxicity require multiple dose reduction enough dose reduction act actually interfere activity profile could big reason doublet may succeeded zanzapem could succeed also point zanza target profile cabo inhibits tam met family result similar immune permissive environment cabo result however tolerability profile zanza differentiated cabo namely start full dos zanza combination io whereas combination cabo started reduced dose course len start reduced dose reduces even thereafter keep eye data leap study head neck pretty confident combination testing head neck zanzapem represent pretty high probability successmichael schmidt guggenheim partner analyst awesome thanks helpful contextsusan hubbard executive vice president public affair investor relation bet michael thank youoperatorthank next question come line jason gerberry bank america line openchi fong bank america merrill lynch analyst hi chi jason thanks taking question one prostate twopart question asco gu presentation discussion around whether second nht chemotherapy appropriate control arm curious regulatory side alignment fda choice control arm contacto commercial side see contact fit treatment algorithm relative chemo radio refractory setting thank youmike morrissey president chief executive officer thanks chi let u amy start comparative question glad asked pj wind commercial stuffamy peterson chief medical officer yeah thanks chi also room discussion dr chi let start every phase control arm every patient disease work collaboration health authority kols ultimately steering committee member design trial maintains equipoise mean equipoise patient presented option enroll study mean treating physician already determined either treatment arm reasonable patient treating physician felt different available treatment option better suited patient would expect patient presented option enroll develop inclusion exclusion criterion discussion health authority kols identify appropriate patient study investigator felt patient candidate patient candidate second nht example mentioned dr chi discussion gu asco symposium high pain score high volume disease expect patient would treated outside clinical trial actually see heterogeneity patient demographic among contemporaneous study conducted similar setting example look patient enrollment demographic contact psma conducted metastatic castrateresistant prostate cancer failed first nht contact patient measurable disease versus psma approximately quarter patient contact received docetaxel metastatic setting versus zero psma patient contact liver disease versus le psma going even pull data metaanalysis conducted susan halabi collaboration dr small asco gu president metaanalysis nine randomized phase study looking docetaxel comparator arm thousand patient look percent patient randomized phase study chemotherapy actually liver metastasis contacto patient liver metastasis difference due inclusion exclusion criterion situation treating physician patient look either arm say appropriate neither appropriate design ethical clinical trial collaboration agreement health authority steering committee pi patient enroll pas pj address commercial landscapepj haley executive vice president commercial great thanks amy first really excited data presenting metastatic castrateresistant prostate cancer really large opportunity patient across line therapy remains significant unmet medical need patient physician treat fiveyear overall survival rate population still think option exist obviously nht would point approximately patient already received nht get firstline castrateresistant setting beyond really got radioligand therapy chemo therapy obviously limitation whether rlp regard logistics issue term mean patient regard around family etc seen repeatedly market research discussion physician many patient physician want either delay receive chemo said believe significant place combination caboatezo approved another thing would point two sort class therapy available postnht really significant need great deal excitement new mechanism action crpc setting obviously regimen two tki well immunotherapy certainly lot potential excitement immunotherapy prostate cancer excited opportunity think broader treating population community oncology physician comfortable obviously checkpoint inhibitor well cabozantinib across board look forward potential spacechi fong bank america merrill lynch analyst great thank yoususan hubbard executive vice president public affair investor relation welcome chioperatorthank please stand next question next question come line gregory renza rbc capital market line openanish nikhanj rbc capital market analyst hi guy anish greg congrats progress quarter thanks taking question current patent litigation msn know speak detail case thinking ahead potential outcome presence cabos exclusivity could share framing best case worstcase outcome msn case relation cabos exclusivity quickly zanza expect update stellar year congrats thanks muchmike morrissey president chief executive officer yeah thanks question take anda question pas amy yes talking specific relative trial obvious reason really want speculate potential outcome scenario kind thing excited opportunity move company forward always right thing patient shareholder continue going forward amyamy peterson chief medical officer sure thanks question stellar multiarm study evaluating zanza combination io monotherapy io like pd pdl additionally bringing agent table example ctla lag many cohort enrolling earlier line therapy going take time data mature really looking forward sharing mature stay tuned might able show anish nikhanj rbc capital market analyst thank yoususan hubbard executive vice president public affair investor relation welcomeoperatorthank please stand next question next question come line jay olson opco line opencheng li oppenheimer company analyst cheng line jay thanks taking question congrats progress also thanks color contacto two question actually regarding data presented asco gu love hear thought first question curious thinking potential launch subcu formulation opdivo actually may create additional momentum uptick cabonivo compared regimen given pretty favorable data saw checkmate also potentially attractive pricing subcu formulation course easier administration second question keynote showing o benefit adjuvant setting expect impact market size potential treatment paradigm advance setting moving forward thank muchmike morrissey president chief executive officer yeah thanks question think pj handle take awaypj haley executive vice president commercial yeah thanks question regard subcu formulation think option physician ultimately patient positive thing convenience overall regimen cabo combination nivolumab firstline rcc certainly good thing could provide momentum end day wait see play regard pembro adjuvant data certainly impressive data overall survival think way talked bit way thought really impressive data great patient obviously good see o benefit regard impact metastatic firstline setting population eligible adjuvant therapy among getting nephrectomy relatively small said impact time firstline setting take time believe play certainly patient quickly recurring either shortly adjuvant treatment heard physician kols think different fashion could provide incremental potential another therapeutic option obviously main one tki good news patient think take time play first line certainly think nothing potential cabocheng li oppenheimer company analyst got thank muchsusan hubbard executive vice president public affair investor relation yeah thank chengoperatorthank please stand next question next question come line asthika goonewardene truist line openasthika goonewardene truist security analyst hi guy thanks taking question appreciate guy super efficient today one quickest prepared remark long would like talk little bit contact please look subsequent therapy bit imbalance patient control arm got chemo patient cabo arm maybe amy michael wondered could comment already saw current separate confident feel o benefit still carry forward despite imbalance related maybe give u little bit color could expect next o work contactamy peterson chief medical officer yeah take question couple embedded first regard subsequent therapy remember showed asco gu patient getting chemotherapy caboatezo arm compared getting chemotherapy second nht arm important one outcome actually measured term patient benefit time subsequent chemotherapy time subsequent chemotherapy delayed caboatezo versus second nht actually believe good thing given especially heard pj knowing know patient get chemotherapy want chemotherapy eligible receive chemotherapy patient population overall delaying time chemotherapy bad thing look o confidence o benefit think going see mean speculate going see however say time analysis interim o analysis target number event conducted analysis still enrolling study conducted analysis patient yet enrolled said early analysis see trend favor caboatezo ie decrement survival hazard ratio median second nht caboatezo different seen study conducted space reported data contemporaneously whether hit final o unknown looking forward hopefully seeing data say achieve primary endpoint radiographic progressionfree survival believe demonstrated showed asco gu clinical benefit clinically meaningful statistically significant itt population significant across subgroup patient consistent matter sliced diced analysis itt population whether apply pcwg working group criterion analysis believe regardless final o show reason support novel tki io combination approval patient met eligibility criterion contact patient visceral disease extrapelvic adenopathy believe riskbenefit profile sufficient enough totality riskbenefit profile sufficient enough conversation regulator look see whether actually proceed approval important know job bring option patient focus getting drug approved physician focus treating patient right therapy approved sort mentioned earlier comment look different patient population exist even study conducted space combination caboatezo novel potential treatment option meet patient met criterion contacto study move already approved agent earlier line study testing different radiolabeled psma agent different chemotherapy agent different line different androgen accesstargeted agent caboatezo first tki io combination demonstrate positive result representing unique treatment option patient believe imperative bring patient believe many kols interacted gu asco believe patient advocacy group interacted believe patient want alternative treatment option approval mean everyone going treated therapy however therapy approved one even seem benefit combination able receive itasthika goonewardene truist security analyst thanks amy really helpful follow congratulation data restraint getting saying something dr chi podium comment maybe squeeze one previous question know stay tuned update could maybe give u little color tell u cohort completed recruitmentamy peterson chief medical officer able give point time multiple cohort completed treatment necessarily mean first read remember follow duration therapy follow progressionfree survival follow o even cohort completed mean data coming monthsasthika goonewardene truist security analyst got ok well stay tuned thanks much taking question guyssusan hubbard executive vice president public affair investor relation betoperatorthank please stand next question next question come line andy hsieh william blair line openandy hsieh william blair company analyst great thanks taking question congratulation achievement clinical financial front also really nice see cabos profound activity virtual metastasis subgroup side getting prostate cancer space want ask specifically pfs delta discussed discussion asco coinciding standing interval curious done planning conduct analysis roll scenario separately regarding arcus collaboration combining zanza hip looking previous cabo plus belzutifan combination appears cabo heavy lifting efficacy front expect differentiation novel combination thank youamy peterson chief medical officer ok get clarification question regard heard couple cabo subgroup sorry cabo comment subgroup data showed asco subgroup pfs rule scenario talking sensoring repeat questionandy hsieh william blair company analyst yes yes certainly yes want comment sensoring yes question guess question specifically talking pfs delta right experimental arm control arm really close scanning interval nine week kind brought discussion curious rule basically delta pfs could potentially artifact scanning intervalamy peterson chief medical officer ok understand question much better regard pfs delta one thing take step back look many parameter clinical benefit improvement single point time general optimal way view treatment effect really based hazard ratio look difference experimental control arm across entire pfs analysis one point estimate ie median referring multiple example benefit median positive hazard ratio resulting approval going way back ipilimumab melanoma really recently belzutifan rcc curve separate median yet clinical benefit identified drug approved going observed study robust pfs finding seen across subgroup similar itt population according pcwg working group criterion believe clinically meaningful pfs benefit especially patient population contact represents overall worse prognosis study conducted space lot patient measurable disease visceral disease itt hazard ratio translates improvement control arm exactly saw median versus month liver met subgroup hazard ratio translates doubling improvement control arm fact median observed trebling effect month patient prior docetaxel hazard ratio translates improvement control arm median saw doubling median pfs month part totality data totality data contacto also consider patient enrolled unique distinct study evaluated drug second nht consider unmet need existent space important outcome looked example mentioned time chemotherapy delayed time chemotherapy caboatezo actually result caboatezo resulted increase time symptomatic skeletal event attainable event patient outcome look also look adverse event profile adverse event profile showed caboatezo versus second nht patient enrolled study tolerated first nht quite well median time prior nht month right patient know toxicity nht tolerate juxtapose toxicity caboatezo look different grant look compared toxicity profile chemotherapy differentiated cytopenia febrile neutropenia alopecia peripheral neuropathy differentiated toxicity profile otherwise available therapy patient furthermore look toxicity profile compare cabo io disease doublet used like kidney cancer oncologist treat prostate cancer toxicity profile nearly identical going back said beginning talk clinical benefit really need consider variety parameter believe met support robust clinically meaningful benefit unique patient population go zanza arcus question ok know went long ok asked zanza given data cabobel real clear belzutifan might bringing anything table let take step back remind everybody talking zanza believe bestinclass vegfr tki drug similar target profile cabo tolerability profile differentiated inaudible rd day presented ikcs patient actually responded zanza progress cabo different think opportunity bestinclass arcus evaluating monotherapy ab see whether emerges bestinclass agent reason bring two potentially active agent together disease really excited stellar cofunded arcus u study test combination patient rcc figure whether might move combination forwardsusan hubbard executive vice president public affair investor relation great andy know multipart question got long queue going need move next question operatoroperatorplease stand next question next question come line yaron weber td cowen line openjoyce zhou td cowen analyst hey guy joyce yaron thanks taking question thanks color contacto maybe one could clarify since study seems enrolled secondline patient well noted patient previously received docetaxel broad label guy aiming whether second line post first nht pre chemo whether also looking get approval post first nht post chemo thanksamy peterson chief medical officer yeah thanks joyce liberty really predict might ultimate label go back first principle clinical trial design design study pay special attention inclusionexclusion criterion discussed regulator would state believe positive study itt patient population first positive global phase study tki io combination metastatic castrationresistant prostate cancer patient progressed least one nht pre postchemo settingjoyce zhou td cowen analyst got thank could squeeze followup looking susan hubbard executive vice president public affair investor relation honest super long list people get happy follow calljoyce zhou td cowen analyst worry thank youoperatorplease stand next question next question come line akash tewari jefferies line openakash tewari jefferies analyst hey thanks much kind million rd expense next year much specifically zanzarelated kind reason ask look cabos development program able share development cost ipsen takeda bristol opportunity potentially zanzas development aggressively company looking term collaborating zanza number two roughly much spend zanzarelated maybe stepping back merck study looking hif alpha pembro versus tki pembro firstline setting obviously hit would pretty significant impact market would love get take whether hif alpha would able show benefit top hif alpha pembro would actually able show benefit versus tkibased regimen bounce last question see combo zanza hifalpha really playing role market thank youmike morrissey president chief executive officer well lot yeah let work backwards real fast asked think three four question certainly want comment competitor study probability success would refer back published data tkis combined hif inhibitor compared contemporaneous say singleagent tki data like cabo contact think draw conclusion obviously want see data data drive process see data look would really refer back published data relative seeing contemporaneous tki data term clinical collaboration yes spoke length jpmorgan update well rd day presentation super proud work done collaboration commercial partner clinical partner cabo think really appropriate way go relative basically expanding opportunity clinically working various partner able run variety trial er contact etc opportunity cofund talked jpmorgan january priority u zanza first started get ball rolling certainly lot discussion around possibility combining zanza checkpoint collaborative potentially cofunding manner want get ahead something say definitive sure share thanks question move time tightakash tewari jefferies analyst thank youoperatorladies gentleman due interest time ask limit one question please stand next question next question come line silvan tuerkcan jmp security line opensilvan tuerkcan jmp security analyst yeah thank taking question congrats quarter question cabo oral plus checkpoint inhibitor prostate cancer label filing even view community setting versus academic setting prostate cancer play also respect potential lack radioisotope community setting see path forward therefore based data already seen especially iv community setting may earlier choice patient thank youmike morrissey president chief executive officer yes great pjpj haley executive vice president commercial yeah thanks question silvan think kind hit salient theme obviously community oncology setting bit different access radioligand therapy ubiquitous talk physician clinician office potentially mean losing patient opportunity think consideration mentioned previously think know performance cabo really aspect combination monotherapy strong community know strong say really large amount physician substantial experience cabo point great clearly community oncologist treat variety malignancy significant experience various checkpoint inhibitor think certainly could nice opportunity u approvedsilvan tuerkcan jmp security analyst great thank pjsusan hubbard executive vice president public affair investor relation operator next question pleaseoperatorplease stand next question next question come line jeff hung morgan stanley line openmichael riad morgan stanley analyst hi michael riad jeff hung thank taking question impact development path x following recent deal catalent specifically adc capability loss like linker payload design site conjugation could company address thanks muchdana aftab chief scientific officer thanks michael dana take question yes learn news catalent immediately reached leadership productive discussion point say confident continuing support program anticipate changemichael riad morgan stanley analyst thank muchsusan hubbard executive vice president public affair investor relation thank michaeloperatorthank please stand next question next question come line etzer darout bmo capital market line openetzer darout bmo capital market analyst great thanks taking question cabo label expansion able provide color comment around sort planned datadriven regulatory filing net prostate cancer also whether regulatory strategy two indication outside yous would yous thank youmike morrissey president chief executive officer yeah would want comment exyous regulatory strategy arm partner amy andor pj say word othersamy peterson chief medical officer sure regard cabinet really exciting data think people familiar patient population poor prognosis observed median time progression placebo three month change month depending whether pnet net close collaboration alliance working hard get complete locked database transferred u hard opine timeline advantage cabinet example cabosun notably blinded independent central radiology review already incorporated study strong partnership alliance looking forward discussion agency say regard cabinet come contacto think already mentioned anticipating final o result sometime however believe data presented asco gu represents data package sufficiently support totality clinical benefit itt patient population ongoing discussion agency best bring front themetzer darout bmo capital market analyst great thank yoususan hubbard executive vice president public affair investor relation welcome operator next question pleaseoperatorour next question come line peter lawson barclays line openpeter lawson barclays analyst great thank question around guidance thought pricing volume especially light ira kind seasonality thinking revenue pj haley executive vice president commercial yeah hi peter pj thanks question ira clearly play year mean specifically price increase certainly want incur inflationrelated penalty regard revenue real good news patient term medicare patient outofpocket limited year approximately next year really early day observing obviously good news patient potential lower outofpocket cost keeping close eye yes track update availablepeter lawson barclays analyst great anything think regard seasonality yearmike morrissey president chief executive officer yeah nothing would comment petersusan hubbard executive vice president public affair investor relation thanks peter operator next question please getting close top houroperatorthank please stand next question next question come line kaveri pohlman btig line openkaveri pohlman btig analyst yeah good evening congrats progress regarding phase head neck cancer trial zanza keytruda mostly replace keytruda monotherapy used patient lower tumor burden also expect work better keytruda chemo combination bulky diseaseamy peterson chief medical officer yeah hi sorry quickly study zanzapembro versus pembro chemotherapycontaining arm former latter right replacing monotherapy keytrudakaveri pohlman btig analyst yes kind like wanted know keytruda monotherapy mostly used lower tumor patient focusing trial wellamy peterson chief medical officer harkening back comment made earlier study inclusion exclusion criterion inclusion criterion require example tumor express cps score greater necessarily limit tumor burden go equipoise treatment arm either treatment arm reasonable patient sitting front physician order randomize speak burden disease would enroll studysusan hubbard executive vice president public affair investor relation great thank amy operator let u take final question pleaseoperatorthank final question come line christopher liu leerink partner line open christopher liu leerink partner analyst thanks question contacto guy median duration tumor exposure four month median progressionfree survival six month wondering key driver difference quick second one guy adcs pipeline wondering technology driving still zymeworksamy peterson chief medical officer take treatment exposure question think actually presented asco gu dose intensity cabo atezo median duration therapy disconnected pfs variety reason patient take chemotherapy break restart get dose reduction restart anything elaborate point timemike morrissey president chief executive officer good dana final answerdana aftab chief scientific officer sure yes newer adcs pipeline using zymeworks primarily smart tag technology catalentmike morrissey president chief executive officer yeah would recommend interested detail pretty fulsome discussion around information rd day december take look webcast think deep understanding broad platform built around linkers warhead various edcssusan hubbard executive vice president public affair investor relation great thank mike thank everybody joining u call today attention question certainly available take followup may great rest dayoperatoroperator signoff duration minutescall participantssusan hubbard executive vice president public affair investor relationsmike morrissey president chief executive officerchris senner chief financial officermichael schmidt guggenheim partner analystamy peterson chief medical officerchi fong bank america merrill lynch analystpj haley executive vice president commercialanish nikhanj rbc capital market analystcheng li oppenheimer company analystasthika goonewardene truist security analystandy hsieh william blair company analystjoyce zhou td cowen analystakash tewari jefferies analystsilvan tuerkcan jmp security analystmichael riad morgan stanley analystdana aftab chief scientific officeretzer darout bmo capital market analystpeter lawson barclays analystkaveri pohlman btig analystchristopher liu leerink partner analyst exel analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool recommends exelixis motley fool disclosure policy